Education
About Us
Working with TipRanks
Follow Us
Avita Medical Ltd (RCEL)
NASDAQ:RCEL
RCEL Stock Chart & Stats
$4.80
-$5.13(-36.49%)
At close: 4:00 PM EST
$4.80
-$5.13(-36.49%)
Day’s Range― - ―
52-Week Range$3.22 - $10.29
Previous CloseN/A
Volume824.49K
Average Volume (3M)221.82K
Market Cap
$121.00M
Enterprise Value$90.02M
Total Cash (Recent Filing)$18.18M
Total Debt (Recent Filing)$2.13M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
May 07, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding30,631,794
10 Day Avg. Volume194,154
30 Day Avg. Volume221,817
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-5.77
Price to Sales (P/S)1.34
P/FCF Ratio-3.08
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit1.53
Enterprise Value/Ebitda-2.18
Forecast
1Y Price Target
$6.33Price Target Upside31.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$82.41M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And AdoptionAccumulating clinical and real-world data showing improved wound healing with the integrated product set enhances clinical credibility and can drive broader clinician adoption and higher revenue per patient.
Credit And Liquidity SupportA new credit agreement that lowers revenue covenants and provides committed capital reduces default risk and increases financial flexibility to support execution and growth plans.
Reimbursement ClarityMedicare contractors publishing payment guidance for RECELL reduces reimbursement uncertainty and helps restore customer confidence, supporting steadier clinician use and sales activity.
Bears Say
Margin CompressionGross profit margin contraction driven by product mix and inventory adjustments is compressing profitability and limiting ability to generate sustainable free cash flow.
Operating Expenses And Cash BurnOperating expenses remain a large share of revenue and rising cash usage is putting pressure on profitability and liquidity, which may heighten reliance on external funding.
Valuation And Execution RiskShares trading at a notably lower valuation than peers reflect prior execution misses and guidance reductions, constraining upside potential despite future operational improvements.
Avita Medical News
RCEL FAQ
What was Avita Medical Ltd’s price range in the past 12 months?
Avita Medical Ltd lowest stock price was $3.22 and its highest was $10.29 in the past 12 months.
What is Avita Medical Ltd’s market cap?
Avita Medical Ltd’s market cap is $121.00M.
When is Avita Medical Ltd’s upcoming earnings report date?
Avita Medical Ltd’s upcoming earnings report date is May 07, 2026 which is in 45 days.
How were Avita Medical Ltd’s earnings last quarter?
Avita Medical Ltd released its earnings results on Feb 12, 2026. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.364 by -$0.016.
Is Avita Medical Ltd overvalued?
According to Wall Street analysts Avita Medical Ltd’s price is currently Undervalued.
Does Avita Medical Ltd pay dividends?
Avita Medical Ltd does not currently pay dividends.
What is Avita Medical Ltd’s EPS estimate?
Avita Medical Ltd’s EPS estimate is -0.29.
How many shares outstanding does Avita Medical Ltd have?
Avita Medical Ltd has 30,631,794 shares outstanding.
What happened to Avita Medical Ltd’s price movement after its last earnings report?
Avita Medical Ltd reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.364. Following the earnings report the stock price went up 11.828%.
Which hedge fund is a major shareholder of Avita Medical Ltd?
Currently, no hedge funds are holding shares in RCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avita Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.33 (31.88% Upside)
$6.33 (31.88% Upside)
Blogger Sentiment
Bullish
RCEL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 14.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $21.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-57.43%
12-Months-Change
Fundamentals
Return on Equity
476.59%
Trailing 12-Months
Asset Growth
-29.25%
Trailing 12-Months
Company Description
Avita Medical Ltd
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
RCEL Company Deck
RCEL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed that 2025 was a year of stabilization and execution discipline: the company delivered FY revenue growth (+11%), maintained gross margins above 80%, reduced operating expenses (~9% FY) and improved net cash use over three consecutive quarters, while securing a more flexible credit facility. Management also restored reimbursement clarity across six of seven MACs and advanced clinical enrollment for CoHiliX and PermeDerm, supporting a 2026 revenue outlook of $80–85M (+12%–19%). Offsetting these positives are Q4 revenue softness (Q4 revenue down ~4.3% YoY), meaningful gross margin compression versus the prior year driven by inventory reserves and product mix, continued high operating expenses (Q4 OpEx exceeded Q4 revenue), and one remaining MAC yet to publish rates. Overall, the company appears to have materially reduced execution and covenant risk and positioned itself for gradual, execution-led growth, while still facing near-term margin and profitability headwinds.View all RCEL earnings summariesRCEL Revenue Breakdown
99.27% Commercial sales
0.67% Services for emergency preparedness
0.07% Deferred commercial revenue
RCEL Stock 12 Month Forecast
Average Price Target
$6.33
▲(31.88% Upside)
Technical Analysis
Ownership Overview
1.88% Insiders
6.16% Mutual Funds
1.05% Other Institutional Investors
84.73% Public Companies and
Individual Investors